Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial - Ismael, Gustavo; Hegg, Roberto; Muehlbauer, Susanne; Heinzmann, Dominik; Lum, Bert; Kim, Sung-Bae; Pienkowski, Tadeusz; Lichinitser, Mikhail; Semiglazov, Vladimir; Melichar, Bohuslav; Jackisch, Christian (The lancet: oncology, 2012)